Progen gets strategic advice
Wednesday, 27 August, 2008
Progen Pharmaceuticals [ASX: PGL] has appointed a new group of corporate advisors to help guide the company's development.
The company has commissioned the services of the independent corporate advisory firm Beerworth and Partners (BPL).
BPL has been hired to assess Progen's operations and develop strategic options to be reviewed by Progen's Board of directors.
The advisory firm will also provide general corporate advice and assist the board as required.
According to Progen, the decision to hire advisors was made when the directors realised the company's strong cash position after terminating the PI88 Phase III Pathway study in liver cancer.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
